Breakthrough in Advanced Liver Cancer Treatment: Promising Results from Combination Therapy Study

New Horizons in Advanced Hepatocellular Carcinoma Treatment?

Recent real-world data showcases promising outcomes for camrelizumab plus apatinib in patients with advanced hepatocellular carcinoma (HCC), offering new insights into this emerging therapeutic approach. Researchers from Handan Central Hospital conducted a retrospective single-arm study involving 39 patients with advanced HCC who received this combination therapy between March 2020 and January 2024. The study's findings reveal significant clinical benefits with manageable toxicity, providing valuable evidence supporting the integration of this regimen into treatment algorithms for advanced HCC. With HCC remaining the third leading cause of cancer-associated mortality worldwide and approximately half of patients diagnosed at advanced stages, these results address an urgent need for effective systemic therapies beyond traditional approaches like sorafenib, which has been the standard first-line treatment for over a decade despite its limitations. The combination of tyrosine kinase inhibitors with immunotherapy represents one of the most promising strategies to improve outcomes in this challenging patient population, with apatinib's antiangiogenic properties potentially synergizing with camrelizumab's immune-modulating effects through programmed cell death protein 1 (PD-1) inhibition. This study builds upon previous clinical trials such as RESCUE and CARES-310, which demonstrated encouraging efficacy for this combination, but provides much-needed real-world validation of these findings while also exploring prognostic factors that might influence treatment outcomes.

Are Patient Characteristics Key to Treatment Success?

The patient cohort represented a typical advanced HCC population, with a mean age of 59.4 years and male predominance (79.5%). Notably, 33.3% of patients presented with portal vein invasion and 43.6% with extrahepatic metastasis, key indicators of advanced disease. The majority (74.4%) received camrelizumab plus apatinib as first-line therapy, while 25.6% received it as second- or later-line treatment. The treatment protocol involved camrelizumab administered at 200 mg intravenously every three weeks combined with daily oral apatinib at 250 mg. Some patients (25.6%) also underwent transarterial chemoembolization (TACE) based on clinical judgment and patient preference. Response assessment occurred every three months using computed tomography or magnetic resonance imaging, with a median follow-up duration of 10 months (range: 1.0-54.0 months). The efficacy results were impressive, with an objective response rate (ORR) of 35.9% and a disease control rate (DCR) of 82.1%. Complete responses were achieved in 25.6% of patients, partial responses in 10.3%, and stable disease in 46.2%, with only 17.9% experiencing disease progression. These response rates align with or exceed those reported in previous clinical trials of this combination therapy, which showed ORRs ranging from 17.3% to 45.7% and DCRs of 57.7% to 78.6%. The notably high complete response rate (25.6%) compared to the 1.1% reported in the CARES-310 phase III trial might be partially attributed to the addition of TACE in some patients, suggesting potential benefits of combining locoregional and systemic approaches in selected cases. However, subgroup analysis showed no statistically significant differences in ORR, DCR, progression-free survival (PFS), or overall survival (OS) between patients who did or did not receive TACE, possibly due to the small sample size or selection of patients with more advanced disease for the combination approach.

Could Improved Survival Outcomes Signal a Shift in HCC Management?

The survival outcomes further underscore the potential of this therapeutic approach, with a median PFS of 24.0 months (95% CI: 5.0-43.0 months) and accumulated PFS rates of 52.8%, 44.0%, and 39.1% at 12, 24, and 36 months, respectively. The median OS was not reached during the follow-up period, with cumulative OS rates of 72.4% at both 12 and 24 months, and 66.3% at 36 months. These results compare favorably with historical outcomes for advanced HCC and exceed those reported in some previous studies of this combination, which found median PFS of 5.5-5.7 months and 12-month OS rates of 68.2-76.5%. The investigators suggest this discrepancy might be explained by differences in baseline characteristics, as the current study included a lower proportion of patients with extrahepatic metastasis (43.6% versus 64.3-75.8% in previous studies) and fewer patients with maximum tumor diameter ≥10 cm (20.5% versus 40.4% in a previous study), potentially indicating a less aggressive disease profile in this cohort. These findings highlight the importance of considering baseline disease characteristics when interpreting efficacy outcomes across different studies and underscore the need for validated prognostic factors to guide patient selection. In multivariate analysis, extrahepatic metastasis emerged as an independent predictor of higher mortality risk (HR 9.217, P=0.049), consistent with previous research indicating its negative prognostic impact. Interestingly, this factor was not significant in univariate analysis, possibly due to the limited sample size affecting statistical power. No other clinical factors were significantly associated with PFS or OS in this cohort, which again may reflect limitations in sample size rather than true absence of prognostic relationships.

How Safe Is the Combination Therapy in Real-World Practice?

The safety profile of camrelizumab plus apatinib in this real-world setting was generally consistent with previous reports, with hematological toxicities being the most common adverse events. Anemia (79.5%), thrombocytopenia (69.2%), and leukopenia (64.1%) were most frequently observed, followed by pain (56.4%), neutropenia (41.0%), and fever (33.3%). The relatively high incidence of pain (56.4%) compared to previous studies (26.8-49.2%) may be related to the use of TACE in a subset of patients. Hypertension, a known class effect of anti-angiogenic agents like apatinib, occurred in 28.2% of patients. Other adverse events included decreased appetite (23.1%), nausea and vomiting (23.1%), diarrhea (7.7%), fatigue (7.7%), and reactive cutaneous capillary endothelial proliferation (RCCEP, 7.7%), a characteristic adverse event associated with camrelizumab. All adverse events were grade 1-2, and treatment modifications were required in only one patient (2.6%), suggesting good tolerability of this regimen in clinical practice. Camrelizumab-specific adverse events included fever (17.9%), RCCEP (7.7%), anemia (5.1%), neutropenia (5.1%), diarrhea (5.1%), thrombocytopenia (2.6%), and fatigue (2.6%). The researchers noted that the incidence of most adverse events was numerically higher with the combination therapy compared to camrelizumab monotherapy based on previous studies, emphasizing the importance of balancing efficacy benefits against the risk of adverse events when choosing between monotherapy and combination regimens. The absence of grade 3-4 toxicities in this cohort is notable and differs somewhat from clinical trial experiences, possibly reflecting differences in patient selection, monitoring practices, or reporting in the real-world setting versus controlled trials. The researchers appropriately acknowledge that further efforts are needed to optimize tolerability while maintaining efficacy.

What Are the Study Limitations and Future Directions for HCC Therapy?

Despite its valuable contributions, the study has several limitations that warrant consideration when interpreting its findings. The retrospective, single-arm design introduces potential selection bias and limits causal inference regarding treatment effects without a control group for comparison. The investigators conducted a post hoc statistical power analysis based on the observed median PFS compared to a previous study, achieving 89.6% power with an alpha of 0.05, but the small sample size still limits statistical power for detecting associations, particularly in subgroup and prognostic factor analyses. The relatively short follow-up period (median 10 months) prevented determination of median OS and may underestimate long-term toxicities or benefits. Additionally, the study included only patients from China, potentially limiting generalizability to other populations with different genetic backgrounds, healthcare systems, or treatment approaches. The researchers appropriately acknowledge these limitations and call for prospective, randomized studies with larger, more diverse cohorts and longer follow-up to confirm their findings. They also highlight the need for further investigation into the potential benefits of combining liver transplantation with camrelizumab and apatinib, as adjuvant therapy following liver transplantation has been reported to improve prognosis in HCC patients. These considerations provide a roadmap for future research to build upon the promising real-world evidence presented in this study. Could the addition of biomarker analyses in future studies help identify patients most likely to benefit from this combination therapy? How might regional variations in HCC etiology (hepatitis B versus C virus, alcohol-related, or NASH-associated) influence outcomes with immunotherapy-TKI combinations? Would sequential treatment strategies involving this combination at different points in the disease trajectory optimize outcomes compared to concurrent administration from the outset? These questions remain to be addressed through carefully designed clinical investigations.

In conclusion, this real-world study provides valuable evidence supporting the efficacy and tolerability of camrelizumab plus apatinib in patients with advanced HCC, with response rates and survival outcomes that compare favorably with historical data and previous studies of this combination. The identification of extrahepatic metastasis as an independent negative prognostic factor provides clinically relevant information for patient counseling and treatment planning. The manageable safety profile, with predominantly low-grade hematological toxicities and minimal need for treatment modifications, suggests good tolerability in clinical practice. While the limitations of the retrospective, single-arm design and small sample size must be acknowledged, these findings contribute to the growing body of evidence supporting the integration of immunotherapy-TKI combinations into the treatment landscape for advanced HCC. As systemic therapy options for HCC continue to evolve rapidly, real-world data like these help bridge the gap between clinical trial results and everyday practice, informing treatment decisions for this challenging malignancy. Could these promising results with camrelizumab plus apatinib lead to changes in treatment guidelines for advanced HCC in the near future? How might the cost-effectiveness of this regimen compare to other approved combinations in different healthcare systems worldwide? What role might circulating biomarkers play in monitoring response and guiding treatment duration with this combination? These questions highlight the ongoing need for both clinical and translational research to optimize outcomes for patients with advanced HCC in the era of combination immunotherapy and targeted therapy.

Summary

A retrospective study of 39 patients with advanced hepatocellular carcinoma (HCC) treated with camrelizumab plus apatinib has revealed promising therapeutic outcomes. The treatment achieved an objective response rate of 35.9% and a disease control rate of 82.1%, with 25.6% of patients achieving complete response. The median progression-free survival was 24.0 months, while overall survival rates remained high at 72.4% at both 12 and 24 months. The therapy showed a manageable safety profile, with primarily grade 1-2 adverse events, mostly hematological in nature. Extrahepatic metastasis emerged as an independent predictor of higher mortality risk. Despite study limitations, including its retrospective nature and small sample size, the results suggest this combination therapy could represent a significant advancement in HCC treatment.